SCHEMBL4864302

SCHEMBL4864302

c1ccc2c(c1)NC1CCCC21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.56
TSHR P16473 1/20 0.56
PARP1 P09874 1/20 0.54
AURKA O14965 1/20 0.42
AURKB Q96GD4 1/20 0.42
NOS2 P35228 3/20 0.38
NLRP3 Q96P20 1/20 0.37
NOS1 P29475 2/20 0.37
NOS3 P29474 1/20 0.37
DRD2 P14416 1/20 0.35
NR3C1 P04150 2/20 0.35
PGR P06401 2/20 0.35
NR3C2 P08235 2/20 0.35
AR P10275 2/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR5A P47898 1/20 0.34
HTR2C P28335 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18271938 1.00 LMNA (0.56) LMNATSHRPARP1AURKAAURKB
SCHEMBL29386048 1.00 LMNA (0.56) LMNATSHRPARP1AURKAAURKB
SCHEMBL18269673 1.00 LMNA (0.56) LMNATSHRPARP1AURKAAURKB
SCHEMBL18324161 1.00 LMNA (0.56) LMNATSHRPARP1AURKAAURKB
SCHEMBL4498580 0.96 LMNA (0.61) LMNATSHRPARP1AURKAAURKB
SCHEMBL9120552 0.96 LMNA (0.61) LMNATSHRPARP1AURKAAURKB
SCHEMBL11304909 0.96 LMNA (0.61) LMNATSHRPARP1AURKAAURKB
SCHEMBL30372866 0.96 LMNA (0.61) LMNATSHRPARP1AURKAAURKB
SCHEMBL18269675 0.96 LMNA (0.61) LMNATSHRPARP1AURKAAURKB
SCHEMBL21077720 0.94 LMNA (0.59) LMNATSHRPARP1AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4284144-A1 LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE SAME Samsung Display Co., Ltd. (KR) 2023-11-29 EP disclosed
CN-117119821-A Light-emitting element, electronic device including the same, and electronic apparatus 三星显示有限公司 2023-11-24 CN disclosed
US-20230380262-A1 LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-23 US disclosed
US-20230134849-A1 PHOTOELECTRIC CONVERSION ELEMENT, PHOTOELECTRIC CONVERSION MODULE, AND ELECTRONIC DEVICE RICOH COMPANY, LTD. (JP) 2023-05-04 US disclosed
US-20230134849-A1 PHOTOELECTRIC CONVERSION ELEMENT, PHOTOELECTRIC CONVERSION MODULE, AND ELECTRONIC DEVICE RICOH COMPANY, LTD. (JP) 2023-05-04 US disclosed
CN-114031547-A Indole compound and application thereof 上海甘田光学材料有限公司 2022-02-11 CN disclosed
US-9748044-B2 Photosensitizer and photoelectric conversion device CHEMICREA INC. (JP) 2017-08-29 US disclosed
US-9748044-B2 Photosensitizer and photoelectric conversion device CHEMICREA INC. (JP) 2017-08-29 US disclosed
US-9697956-B2 Diketopyrrolopyrole (DPP)-based sensitizers for electrochemical or optoelectronic devices ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2017-07-04 US disclosed
US-9697956-B2 Diketopyrrolopyrole (DPP)-based sensitizers for electrochemical or optoelectronic devices ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2017-07-04 US disclosed
US-7141563-B2 Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives WYETH (US) 2006-11-28 US disclosed
US-20050004101-A1 Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives WYETH (US) 2005-01-06 US disclosed
EP-1330457-B1 CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS WYETH CORP (US) 2004-10-20 EP disclosed
US-6777407-B2 7BH-CYCLOPENTA(B)(1,4)DIAZEPINO(6, 7, 1-HI)INDOLE OR A SALT, USEFUL FOR TREATMENT OF SCHIZOPHRENIA, OBSESSIVE COMPULSIVE DISORDER, DEPRESSION, ANXIETY, PANIC DISORDER, OBESITY OR EPILEPSY WYETH 2004-08-17 US disclosed
US-6777407-B2 7BH-CYCLOPENTA(B)(1,4)DIAZEPINO(6, 7, 1-HI)INDOLE OR A SALT, USEFUL FOR TREATMENT OF SCHIZOPHRENIA, OBSESSIVE COMPULSIVE DISORDER, DEPRESSION, ANXIETY, PANIC DISORDER, OBESITY OR EPILEPSY WYETH 2004-08-17 US disclosed
EP-1330457-A2 CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS Wyeth (US) 2003-07-30 EP disclosed
US-20020107242-A1 Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives AMERICAN HOME PRODUCTS CORPORATION 2002-08-08 US disclosed
WO-2002042304-A2 CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS WYETH (US) 2002-05-30 WO disclosed
US-20020058689-A1 Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi]indole derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 2002-05-16 US disclosed
US-4755505-A 1-[2-(dialkylamino)alkyl]-4,5-dihydro-4-(aryl)-1-benzazocine-2,6(1H,3H)-diones as anti-arrhythmic agents AMERICAN HOME PRODUCTS CORPORATION (US) 1988-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107242-A1 Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives CNR1, HCRTR1, HTR3C LMNA 3061/4885TSHR 481/4885PARP1 1209/4885
US-20020058689-A1 Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi]indole derivatives HRH3, HTR1A, HTR7 LMNA 3537/4885TSHR 378/4885PARP1 730/4885
US-20050004101-A1 Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives CNR1, HCRTR1, HTR3C LMNA 3207/4885TSHR 371/4885PARP1 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.